However, knocking down the expression of MFHAS1 in macrophages reduces the number of M2 TAMs and delays the progression of CRC (58), which also means that MFFAS1 in macrophages is also one of the most potential targets for tumor immunotherapy. The gene discussed is MFHAS1; the disease is colorectal carcinoma.